Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension
- PMID: 17567935
- DOI: 10.1152/ajprenal.00507.2006
Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension
Abstract
Hypertension is a likely consequence of chronic lead exposure in humans, especially in association with reduced renal function and in high risk populations. Numerous studies have demonstrated that oxidative stress plays an important role in the pathogenesis of experimental lead-induced hypertension and we have shown recently that tubulointerstitial immune cell infiltration is a feature of chronic low-dose lead exposure. Since oxidative stress, renal inflammation, and angiotensin activity are closely linked characteristics in experimental models of hypertension, we decided to investigate whether lead-induced hypertension would be ameliorated by suppressing renal inflammation with the immunosuppressive drug mycophenolate mofetil (MMF). We studied rats exposed for 14 wk to lead acetate (100 ppm in the drinking water) that, in addition, received either MMF, 20 mg.kg(-1).day(-1) by gastric gavage (Pb.MMF group, n = 12) or vehicle (Pb group, n = 12). Control rats received MMF alone (n = 5) or neither lead nor MMF (n = 6). All rats were killed at the end of the experiment. Low-dose lead exposure resulted in mild to moderate tubular cell damage and a progressive increment in blood pressure, oxidative stress, interstitial accumulation of lymphocytes and macrophages, NF-kappaB activation, and increased renal angiotensin II level. The administration of MMF suppressed the tubulointerstitial accumulation of lymphocytes and macrophages and prevented the hypertension, oxidative stress, and NF-kappaB activation and reduced the heightened renal angiotensin content associated with chronic lead exposure. We conclude that interstitial inflammation plays an important role in lead-induced hypertension.
Similar articles
-
Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.Kidney Int. 1999 Mar;55(3):945-55. doi: 10.1046/j.1523-1755.1999.055003945.x. Kidney Int. 1999. PMID: 10027931
-
Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure.Kidney Int. 2001 Jun;59(6):2222-32. doi: 10.1046/j.1523-1755.2001.00737.x. Kidney Int. 2001. PMID: 11380825
-
Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension.Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1018-25. doi: 10.1152/ajpheart.00487.2006. Epub 2006 Oct 13. Am J Physiol Heart Circ Physiol. 2007. PMID: 17040973
-
Role of immunocompetent cells in nonimmune renal diseases.Kidney Int. 2001 May;59(5):1626-40. doi: 10.1046/j.1523-1755.2001.0590051626.x. Kidney Int. 2001. PMID: 11318933 Review.
-
Mycophenolate mofetil--a new atheropreventive drug?Acta Pol Pharm. 2014 May-Jun;71(3):353-61. Acta Pol Pharm. 2014. PMID: 25265813 Review.
Cited by
-
Cardiovascular effects of immunosuppression agents.Front Cardiovasc Med. 2022 Sep 21;9:981838. doi: 10.3389/fcvm.2022.981838. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36211586 Free PMC article. Review.
-
Role of the adaptive immune system in hypertension.Curr Opin Pharmacol. 2010 Apr;10(2):203-7. doi: 10.1016/j.coph.2010.01.006. Epub 2010 Feb 17. Curr Opin Pharmacol. 2010. PMID: 20167535 Free PMC article. Review.
-
Connexin 43 in splenic lymphocytes is involved in the regulation of CD4+CD25+ T lymphocyte proliferation and cytokine production in hypertensive inflammation.Int J Mol Med. 2018 Jan;41(1):13-24. doi: 10.3892/ijmm.2017.3201. Epub 2017 Oct 20. Int J Mol Med. 2018. PMID: 29115377 Free PMC article.
-
Amplification of Salt-Sensitive Hypertension and Kidney Damage by Immune Mechanisms.Am J Hypertens. 2021 Feb 18;34(1):3-14. doi: 10.1093/ajh/hpaa124. Am J Hypertens. 2021. PMID: 32725162 Free PMC article. Review.
-
Microglia and Monocyte-Derived Macrophages in Stroke.Neurotherapeutics. 2016 Oct;13(4):702-718. doi: 10.1007/s13311-016-0463-1. Neurotherapeutics. 2016. PMID: 27485238 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical